Cinnarizine
From Wikipedia, the free encyclopedia
Cinnarizine
|
|
Systematic (IUPAC) name | |
1-benzhydryl-4-cinnamyl-piperazine | |
Identifiers | |
CAS number | |
ATC code | N07 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C26H28N2 |
Mol. mass | 368.514 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Cinnarizine is an anti-histaminic drug which is mainly used for the control of vomiting due to motion sickness. It is marketed under the brand Stugeron or Stunarone and is not available over the counter in North America. Cinnarizine was first synthesized by Janssen Pharmaceutica in 1955.
It acts by interfering with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus. The disparity of signal processing between inner ear motion receptors and the visual senses is abolished, so that the confusion of brain whether the individual is moving or standing is reduced. Vomiting in motion sickness is actually a physiological compensatory mechanism of the brain to keep the individual from moving so that it can adjust to the signal perception.[citation needed]
Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. It is also effectively combined with other nootropics, primarily piracetam; in such combination each drug potentiate the other in boosting brain oxygen supply.[citation needed]
[edit] References
- Barrett RJ Jr, Zolov B, A clinical evaluation of cinnarizine (Mitronal) in various allergic disorders, J Maine Med Assoc. 1960 Dec;51:454-7.
- Towse G., Cinnarizine--a labyrinthine sedative, J Laryngol Otol. 1980 Sep;94(9):1009-15.
|
|